☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
EyePoint Pharmaceuticals
EyePoint Pharmaceuticals Reports Data From Ongoing P-II (VERONA) Study of Duravyu in Diabetic Macular Edema (DME)
October 29, 2024
EyePoint Pharmaceuticals Reports the First Patient Dosing in P-III (LUGANO) Study of Duravyu to Treat Wet Age-Related Macular Dege...
October 25, 2024
EyePoint Pharmaceuticals Reports the P-II (PAVIA) Study Data of Duravyu for Non-Proliferative Diabetic Retinopathy
May 6, 2024
EyePoint Pharmaceuticals Reports Results for EYP-1901 in P-II Trial for the Treatment of Wet Age-Related Macular Degeneration
February 5, 2024
Load more...
Back to Home
Modal title
×
Modal body text goes here.